Utilizing NOAC's in Non-Valvular Atrial Fibrillation Patients Undergoing PCI
This independent medical education (IME) series has been created for English, German and Spanish speaking cardiologists and is designed to showcase the latest updates emerging from the data in novel oral anticoagulants in non-valvular atrial fibrillation patients undergoing PCI.
It will consider the latest recommendations on bleeding risks and the impact this has on the optimum duration of therapy with NOACs, for those patients with atrial fibrillation. In particular, the WOEST, PIONEER and RE-DUAL-PCI studies will be considered.
Upon completion of this activity, participants will:
- Apply knowledge gained on the complex nature of antithrombotic therapies in non-valvular AF patients undergoing PCI in a range of clinical scenarios
- Increase knowledge on the complications surrounding triple antithrombotic therapy
- Understand the latest clinical evidence regarding the use of NOAC therapy in AF patients undergoing PCI
Robert A Byrne
Stefan H Hohnloser
This content is supported via an unrestricted educational grant from Boehringer Ingelheim:
Key Learning Objectives
- Describe the complex nature and current recommendations for antithrombotic therapy for non-valvular AF patients undergoing PCI
- Define the complications associated with TAT
- Summarize the latest data utilizing NOAC therapy in AF patients undergoing PCI
This webinar is aimed at:
- Interventional cardiologists
- General cardiologists
Robert A Byrne
Professor Robert Byrne is Director of Cardiology at the Mater Private Hospital, Dublin, and Chair of Cardiovascular Research at the Royal College of Surgeons.
He is also head of the Cardiovascular Research Institut(CVRI Dublin) which is a collaboration with the Royal College of Surgeons in Ireland (RCSI). Its research focus is on Outcomes Research, Clinical Trials, Core Laboratory and Systematic Reviews.
Professor Byrne’s internship and general medical training was in the Mater Hospital, Dublin and Mayo Clinic, Arizona. His Cardiology fellowship was in Ireland and at the German Heart Centre, Munich, Germany.
Since then he has held several strategic positions at German Heart Centre, including Consultant Cardiologist and Deputy Director of Cardiology. He returns to Ireland to the role of Director of Cardiology at Mater Private Hospital and RCSI Chair of Cardiovascular Research.
Professor Byrne’s specialty interests are in the field of general and interventional cardiology, coronavirus and heart diesease. Specific areas of expertise are in cardiac catheterization, angioplasty and stenting, optical coherence tomography imaging, interventions for hypertrophic cardiomyopathy (alcohol septal ablation), transcatheter mitral valve repair, left atrial appendage occlusion and patent foramen ovale closure.
Dr Georg Nickenig is a Full Professor and Chair, Department of Internal Medicine and Polyclinic II, University Hospital Bonn, Germany.
Dr Nickenig completed his doctoral degree in Clinical Medicine from the University of Bonn.
Stefan H Hohnloser
Stefan H Hohnloser is Professor of Medicine and Cardiology at the Johann Wolfgang Goethe University in Frankfurt, Germany, where he is the Head of the Department of Electrophysiology. His primary research interests include sudden cardiac death and its prevention by device therapy.
Head of Cardiology, University Hospital Ramón y Cajal, Madrid, Spain
Chief Cardiologist, Hospital University La Paz, Madrid, Spain